e-Drug3D

1915

LAROTRECTINIB

INN
LAROTRECTINIB

cas 1223403-58-4

CLASS

ANTINEOPLASTIC
KINASE INHIBITOR
TREATMENT OF SOLID TUMOR
INHIBITOR OF THE TROPOMYOSIN RECEPTOR KINASES (TRK), TRKA, TRKB, AND TRKC

ROUTE (list)

ORAL

ATC code

L01EX12

PK parameters

F 34 PERCENT
Tmax 1 HOUR
VD 48 LITER
Cl 98 LITER / HOUR
PPB 70 PERCENT
t1/2 2.9 HOUR

Solubility

FREELY SOLUBLE IN WATER AT PH 6.8

Target

TARGET TROPOMYOSIN RECEPTOR KINASE

DrugCentral

High affinity nerve growth factor receptor UNIPROT P04629 NTRK1

BDNF,NT-3 growth factors receptor UNIPROT Q16620 NTRK2

Download SDF file

1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-

Formula:
C21H22F2N6O2

Calculated chemical properties:

MW 428.45
NB_atoms 31
XLogP 2.95
PSA 79.687
NB_HD 2
NB_HA 8
fsp3 0.38
Lipinski(0=no;1=yes) 1

FDA
NDA 210861 (label) INN (LAROTRECTINIB SULFATE) VITRAKVI (BAYER HLTHCARE) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY
NDA 211710 (label) INN (LAROTRECTINIB SULFATE) VITRAKVI (BAYER HEALTHCARE) APPROVAL= AP YEAR= 2018